BLRX News and Press, BioLineRx Ltd. From 10/30/20

Thinly traded nano cap BioLineRx (BLRX) jumps 45% premarket on robust volume in reaction to positive preliminary results from a Phase 3 clinical trial, GENESIS, evaluating lead candidate motixafortide for stem cell mobilization in multiple myeloma patients.Based on a preplanned inte...

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization - Enrollment to cease immediately; topline data anticipated in H1 2021- PR Newswire TEL AVIV, Israel, Oct. 30, 2020 TEL AVIV...

BioLineRx (BLRX) perks 7% premarket after announcing that its lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line metastatic pan...

BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer - Investigator-initiated Phase 2 study, led by Columbia University, to evaluate Motixafortide in combination with LIBTAYO® and chemotherapy in first-line metastatic pancreati...

Turning Point reports positive data for tumor drug candidate Turning Point Therapeutics ( TPTX ) reported positive preliminary data from its Phase 2 clinical trial TRIDENT-1. The trial is designed to assess the potential of repotrectinib in treating patients with ALK-, ROS1- or NTRK-3-mu...

BioLineRx (NASDAQ: BLRX ) announces that enough patients have been enrolled in the Phase 3 GENESIS study to allow for an interim efficacy analysis in H2. If the primary endpoint is met, it intends to stop further recruitment and report topline results in H1 2021. If the primary objecti...

TEL AVIV, Israel , Aug. 19, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in t...

BioLine RX Ltd (BLRX) Q2 2020 Earnings Conference Call August 06, 2020, 10:00 ET Company Participants Timothy McCarthy - LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical Development Conference Call Participants Joseph Pantginis - H.C. Wai...

biolinerx (NASDAQ: BLRX ) : Q2 GAAP EPS of -$0.03 beats by $0.57 . More news on: BioLineRx Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update. Highlights and ...